-
1.发明公开公开(公告)号：US20240131025A1
公开(公告)日：2024-04-25
申请号：US18500735
申请日：2023-11-01
发明人： Dragan Cicic
IPC分类号： A61K31/496 , A61K51/10 , A61P35/02 , C07K16/28
CPC分类号： A61K31/496 , A61K51/1069 , A61P35/02 , C07K16/2803
摘要： This invention provides a method for treating a subject afflicted with cancer, comprising administering to the subject (i) a BCL-2 inhibitor in conjunction with (ii) an alpha-emitting isotope-labeled agent that targets cancer cells in the subject, wherein the amounts of the BCL-2 inhibitor and labeled agent, when administered in conjunction with one another, are therapeutically effective. This invention also provides a method for inducing the death of a cancer cell, comprising contacting the cell with (i) a BCL-2 inhibitor in conjunction with (ii) an alpha-emitting isotope-labeled agent that targets the cancer cell, wherein the amounts of BCL-2 inhibitor and labeled agent, when concurrently contacted with the cell, are effective to induce the cell's death.
-
公开(公告)号：US11364235B2
公开(公告)日：2022-06-21
申请号：US16607168
申请日：2018-04-26
发明人： Dragan Cicic
IPC分类号： A61K31/496 , A61P35/02 , A61K51/10 , C07K16/28
摘要： This invention provides a method for treating a subject afflicted with cancer, comprising administering to the subject (i) a BCL-2 inhibitor in conjunction with (ii) an alpha-emitting isotope-labeled agent that targets cancer cells in the subject, wherein the amounts of the BCL-2 inhibitor and labeled agent, when administered in conjunction with one another, are therapeutically effective. This invention also provides a method for inducing the death of a cancer cell, comprising contacting the cell with (i) a BCL-2 inhibitor in conjunction with (ii) an alpha-emitting isotope-labeled agent that targets the cancer cell, wherein the amounts of BCL-2 inhibitor and labeled agent, when concurrently contacted with the cell, are effective to induce the cell's death.
-
公开(公告)号：US20220273648A1
公开(公告)日：2022-09-01
申请号：US17745045
申请日：2022-05-16
发明人： Dragan Cicic
IPC分类号： A61K31/496 , A61P35/02 , A61K51/10 , C07K16/28
摘要： This invention provides a method for treating a subject afflicted with cancer, comprising administering to the subject (i) a BCL-2 inhibitor in conjunction with (ii) an alpha-emitting isotope-labeled agent that targets cancer cells in the subject, wherein the amounts of the BCL-2 inhibitor and labeled agent, when administered in conjunction with one another, are therapeutically effective. This invention also provides a method for inducing the death of a cancer cell, comprising contacting the cell with (i) a BCL-2 inhibitor in conjunction with (ii) an alpha-emitting isotope-labeled agent that targets the cancer cell, wherein the amounts of BCL-2 inhibitor and labeled agent, when concurrently contacted with the cell, are effective to induce the cell's death.
-
公开(公告)号：US11292835B2
公开(公告)日：2022-04-05
申请号：US16300672
申请日：2017-05-25
发明人： Dragan Cicic
摘要： This invention provides a method for treating a subject afflicted with a hematologic malignancy comprising administering to the subject an agent targeting a hematologic malignancy-associated antigen, wherein the subject has a low peripheral cancerous cell burden. This invention also provides a method for treating a subject afflicted with a hematologic malignancy and having a high peripheral cancerous cell burden, comprising (i) medically lowering the subject's peripheral cancerous cell burden, and (ii) while the subject's peripheral cancerous cell burden is still low, administering to the subject an agent targeting a hematologic malignancy-associated antigen. Particularly envisioned are the subject methods for treating acute myeloid leukemia using an anti-CD33 antibody labeled with an alpha-emitting isotope, such as 225Ac-HuM195.
-
5.发明公开公开(公告)号：US20240226095A9
公开(公告)日：2024-07-11
申请号：US18500735
申请日：2023-11-02
发明人： Dragan Cicic
IPC分类号： A61K31/496 , A61K51/10 , A61P35/02 , C07K16/28
CPC分类号： A61K31/496 , A61K51/1069 , A61P35/02 , C07K16/2803
摘要： This invention provides a method for treating a subject afflicted with cancer, comprising administering to the subject (i) a BCL-2 inhibitor in conjunction with (ii) an alpha-emitting isotope-labeled agent that targets cancer cells in the subject, wherein the amounts of the BCL-2 inhibitor and labeled agent, when administered in conjunction with one another, are therapeutically effective. This invention also provides a method for inducing the death of a cancer cell, comprising contacting the cell with (i) a BCL-2 inhibitor in conjunction with (ii) an alpha-emitting isotope-labeled agent that targets the cancer cell, wherein the amounts of BCL-2 inhibitor and labeled agent, when concurrently contacted with the cell, are effective to induce the cell's death.
-
公开(公告)号：US11844799B2
公开(公告)日：2023-12-19
申请号：US17745045
申请日：2022-05-16
发明人： Dragan Cicic
IPC分类号： A61K31/496 , A61P35/02 , A61K51/10 , C07K16/28
CPC分类号： A61K31/496 , A61K51/1069 , A61P35/02 , C07K16/2803
摘要： This invention provides a method for treating a subject afflicted with cancer, comprising administering to the subject (i) a BCL-2 inhibitor in conjunction with (ii) an alpha-emitting isotope-labeled agent that targets cancer cells in the subject, wherein the amounts of the BCL-2 inhibitor and labeled agent, when administered in conjunction with one another, are therapeutically effective. This invention also provides a method for inducing the death of a cancer cell, comprising contacting the cell with (i) a BCL-2 inhibitor in conjunction with (ii) an alpha-emitting isotope-labeled agent that targets the cancer cell, wherein the amounts of BCL-2 inhibitor and labeled agent, when concurrently contacted with the cell, are effective to induce the cell's death.
-
-
-
-
-
搜索结果
6 条记录 (耗时 0.011 秒)
